Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B-cell Malignancy: early-phase trial registry
4 of 4 indexed B-cell Malignancy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
B-cell Malignancy: 4 US clinical trials tracked, 4 recruiting.
B-cell Malignancy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is BeOne Medicines, running 2 of these trials.
Enrollment posture brief
Registry condition b-cell-malignancy
OPEN 4 | RECR 100% | LATE 0 | EARLY 4 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
B-cell Malignancy lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for B-cell Malignancy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
B-cell Malignancy is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines
NCT05006716
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
NCT05643742
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences
NCT05602363
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
NCT06634589
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on B-cell Malignancy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on B-cell Malignancy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this B-cell Malignancy page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 B-cell Malignancy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- BeOne Medicines sponsors the most B-cell Malignancy trials on record, review their full trial history before evaluating a specific study. See BeOne Medicines's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B-cell Malignancy condition card totals 4 registered trials; most-linked intervention BGB-16673; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.